Avadomide (CC-122) is primarily investigated for its potential in treating various hematologic malignancies and solid tumors due to its immunomodulatory and antineoplastic properties. It functions as a cereblon E3 ubiquitin ligase modulator, leading to the degradation of key transcription factors involved in cancer cell survival and proliferation. This mechanism results in inhibition of tumor growth and induction of apoptosis in malignant cells. It has shown particular promise in clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma and multiple myeloma. Additionally, Avadomide exhibits anti-inflammatory and immunostimulatory effects, making it a candidate for combination therapies with other agents such as monoclonal antibodies or checkpoint inhibitors to enhance antitumor immune responses. Research is also exploring its use in inflammatory and autoimmune conditions, although oncology remains the primary therapeutic focus.